Citizens JMP analyst Constantine Davides lowered the firm’s price target on Evolent Health (EVH) to $11 from $13 and keeps an Outperform rating on the shares. Bookings momentum continued in Q3, but membership dynamics remain fluid ahead of 2026, the analyst tells investors in a research note. The firm continues to view 2025 as a trough earnings year and remains constructive on the embedded longer-term margin opportunity of Evolent’s existing contracts and on the expectation for recent bookings momentum to extend into 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health Inc. Reports Strong Q3 Earnings and Strategic Growth
- Evolent Health’s Strong Q3 Performance and Future Growth Potential Underpin Buy Recommendation
- Evolent Health Reports Strong Q3 2025 Results
- Evolent Health: Strategic Growth Potential Amidst Near-Term Challenges
- Evolent Health Announces Leadership Changes Amid Growth